ANDAORALTABLET, DELAYED RELEASE
Approved
Mar 2014
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ACAMPROSATE CALCIUM (acamprosate calcium enteric-coated) by Viatris (2) is understood. First approved in 2014.
Drug data last refreshed 18h ago
Mechanism of Action
understood. Chronic alcohol exposure is hypothesized to alter the normal balance between neuronal excitation and inhibition. In vitro and in vivo studies in animals have provided evidence to suggest acamprosate may interact with glutamate and GABA neurotransmitter systems centrally, and has led to…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Viatris (2)
China - Shanghai
Worked on ACAMPROSATE CALCIUM at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.